Vitamin D and immunity

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Lucas, Robyn M ^a,b   Gorman, Shelley ^a   Geldenhuys, Sian ^a   Hart, Prue H ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL FLORA; BONE MINERALIZATION; CALCIUM METABOLISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; INFECTION; INNATE IMMUNITY; MICROBIOME; MULTIPLE SCLEROSIS; NONHUMAN; RISK FACTOR; SUN EXPOSURE; ULTRAVIOLET RADIATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84915820061     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-118     Document Type: Article

References (93)

1. Simpson S, Jr., Blizzard L, Otahal P, Van der Mei I, Taylor B: Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011, 82:1132-41.
2. Ball SJ, Haynes A, Jacoby P, Pereira G, Miller LJ, Bower C, Davis EA: Spatial and temporal variation in type 1 diabetes incidence in Western Australia from 1991 to 2010: increased risk at higher latitudes and over time. Health and Place 2014, 28:194-204.
3. Gatenby PA, Lucas RM, Engelsen O, Ponsonby AL, Clements M: Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum 2009, 61:1417-24.
4. Khalili H, Huang ES, Ananthakrishnan AN, Higuchi L, Richter JM, FuchsCS, Chan AT:Geographical variationand incidenceof inflammatory bowel disease among US women. Gut 2012, 61:1686-92.
5. Krstic G: Asthma prevalence associated with geographical latitude and regional insolation in the United States ofAmerica and Australia. PLoS One 2011, 6:e18492.
6. Prieto S, Grau JM: The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010, 9:A330-34.
7. Staples JA, Ponsonby AL, Lim LL, McMichael AJ: Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect 2003, 111:518-23.
8. Hart PH, Gorman S, Finlay-Jones JJ: Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat Rev Immunol 2011, 11:584-96.
9. Nghiem DX, Kazimi N, Clydesdale G, Ananthaswamy HN, Kripke ML, Ullrich SE: Ultraviolet a radiation suppresses an established immune response: implications for sunscreen design. J Invest Dermatol 2001, 117:1193-9.
10. Norval M, Woods GM: UV-induced immunosuppression and the efficacy of vaccination. Photochem Photobiol Sci 2011, 10:1267-74.
11. Zodpey SP, Shrikhande SN: The geographic location (latitude) of studies evaluating protective effect of BCG vaccine and it's efficacy/effectiveness against tuberculosis. Indian J Public Health 2007, 51:205-10.
12. Hewer S, Lucas R, van der Mei I, Taylor BV: Vitamin D and multiple sclerosis. J Clin Neurosci 2013, 20:634-41.
13. Gatenby P, Lucas R, SwaminathanA: VitaminDdeficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol 2013, 25:184-91.
14. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Jama 2006, 296:2832-8.
15. Munger KL, Levin LI, Massa J, Horst R, Orban T, Ascherio A: Preclinical serum 25-hydroxyvitamin D levels and risk of type 1 diabetes in a cohort of US military personnel. Am J Epidemiol 2013, 177:411-9.
16. Simpson M, Brady H, Yin X, Seifert J, Barriga K, Hoffman M, Bugawan T, Baron AE, Sokol RJ, Eisenbarth G, Erlich H, Rewers M, Norris JM: No association of vitaminDintake or 25-hydroxyvitaminDlevels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 2011, 54:2779-88.
17. Autier P, Boniol M, Pizot C, Mullie P: Vitamin D status and ill health: a systematic review. Lancet Diabetes and Endocrinology 2013, 2:76-89.
18. Lucas R, Taylor B: Challenges in exposure and outcome definition in neuroepidemiology: the case of vitamin D and multiple sclerosis. Australasian Epidemiologist 2013, 20:4-8.
19. Mora JR, Iwata M, von Andrian UH: Vitamin effects on the immune system: vitamins A and D take centre stage. Nature reviews Immunology 2008, 8:685-98.
20. Kundu R, Chain BM, Coussens AK, Khoo B, Noursadeghi M: Regulation of CYP27B1 and CYP24A1 hydroxylases limits cell-autonomous activation of vitaminD in dendritic cells. Eur J Immunol 2014, 44:1781-90.
21. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M: Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008, 29:726-76.
22. Penna G, Adorini L: 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000, 164:2405-11.
23. Hilkens CM, Isaacs JD, Thomson AW: Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 2010, 29:156-83.
24. Ferreira GB, Gysemans CA, Demengeot J, da Cunha JP, Vanherwegen AS, Overbergh L, Van Belle TL, Pauwels F, Verstuyf A, Korf H, Mathieu C: 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol 2014, 192:4210-20.
25. Chambers ES, Suwannasaen D, Mann EH, Urry Z, Richards DF, Lertmemongkolchai G, Hawrylowicz CM: 1alpha,25-dihydroxyvitaminD3 in combination with TGFbeta increases the frequency of Foxp3+ Tregs through preferential expansion and usage of IL-2. Immunology 2014, 143:52-60.
26. Gorman S, Judge MA, Hart PH: Topical 1,25-dihydroxyvitamin D3 subverts the priming ability of draining lymph node dendritic cells. Immunology 2010, 131:415-25.
27. Kongsbak M, Levring TB, Geisler C, von Essen MR: The vitamin D receptor and T cell function. Front Immunol 2013, 4:148.
28. Baeke F, Korf H, Overbergh L, Verstuyf A, Thorrez L, Van Lommel L, Waer M, Schuit F, Gysemans C, Mathieu C: The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces amigratory signature specific for homing to sites of inflammation. J Immunol 2011, 186:132-42.
29. Grishkan IV, Fairchild AN, Calabresi PA, Gocke AR: 1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization. Proc Natl Acad Sci USA 2013, 110:21101-6.
30. Chang JH, Cha HR, Lee DS, Seo KY, Kweon MN: 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H) 17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One 2010, 5:e12925.
31. Riek AE, Oh J, Bernal-Mizrachi C: 1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol metabolism in type 2 diabetic patients. J Steroid Biochem Mol Biol 2013, 136:309-12.
32. Gorman S, Judge MA, Burchell JT, Turner DJ, Hart PH: 1,25-dihydroxyvitamin D3 enhances the ability of transferred CD4+ CD25+ cells to modulate T helper type 2-driven asthmatic responses. Immunology 2010, 130:181-92.
33. Gorman S, Judge MA, Hart PH: Gene regulation by 1,25-dihydroxyvitamin D3 in CD4+CD25+ cells is enabled by IL-2. The Journal of investigative dermatology 2010, 130:2368-76.
34. Yip KH, KolesnikoffN, Yu C, HauschildN, Taing H, Biggs L, GoltzmanD, Gregory PA, Anderson PH, Samuel MS, Galli SJ, Lopez AF, Grimbaldeston MA: Mechanisms of vitamin D3 metabolite repression of IgE-dependent mast cell activation. J Allergy Clin Immunol. 2014, 133:1356-64 e1314.
35. Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z, Kaur S, Raza K, SansomDM: Availability of 25-hydroxyvitaminD(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol 2012, 189:5155-64.
36. Davenport C: Multiple sclerosis from the standpoint of geographic distribution and race. Arch Neurol Psychiat 1922, 8:51.
37. Acheson ED, Bachrach CA: The distribution of multiple sclerosis in U.S. veterans by birthplace. Am J Hyg 1960, 72:88-99.
38. Acheson ED, Bachrach CA, Wright FM: Some comments on the relationship of the distribution of Multiple Sclerosis to latitude, solar radiation and other variables. Acta Psychiatr Scand Suppl 1960, 35(S147):132-47.
39. Kampman MT, Wilsgaard T, Mellgren SI: Outdoor activities and diet in childhood and adolescence relate toMS risk above theArctic Circle. J Neurol 2007, 254:471-7.
40. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T: Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Bmj 2003, 327:316-21.
41. Lucas RM, Ponsonby AL, Dear K, Valery PC, Pender MP, Taylor BV, Kilpatrick TJ, Dwyer T, Coulthard A, Chapman C, van der Mei I, Williams D, McMichael AJ: Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011, 76:540-8.
42. Burton JM, Kimball S, Vieth R, Bar-Or A,DoschHM,Cheung R,GagneD, D'Souza C, Ursell M, O'Connor P: A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74:1852-9.
43. Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, Tienari P, Atula S, Sarasoja T, Herrala L, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M: A randomised, double blind, placebo controlled trial with vitaminD3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012, 83:565-71.
44. Becklund BR, Severson KS, Vang SV, Deluca HF: UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Nat Acad Sci USA 2010, 107:6418-23.
45. Breuer J, Schwab N, Schneider-Hohendorf T, Marziniak M, Mohan H, Bhatia U, Gross CC, Clausen BE, Weishaupt C, Luger TA, Meuth SG, Loser K, Wiendl H: Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann Neurol 2014, 75:739-58.
46. Zivadinov R, Treu CN, Weinstock-Guttman B, Turner C, Bergsland N, O'Connor K, Dwyer MG, Carl E, Ramasamy DP, Qu J, Ramanathan M: Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013, 84:1075-81.
47. McLeod JG, Hammond SR, Kurtzke JF: Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration. J Neurol 2011, 258:1140-9.
48. Kurtzke JF, Beebe GW, Norman JE, Jr.: Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 1985, 35:672-8.
49. Disanto G, Chaplin G, Morahan JM, Giovannoni G, Hypponen E, Ebers GC, Ramagopalan SV: Month of birth, vitamin D and risk of immune mediated disease: a case control study. BMC Med 2012, 10:69.
50. Saastamoinen KP, Auvinen MK, Tienari PJ: Month of birth is associated with multiple sclerosis but not with HLA-DR15 in Finland. Multiple sclerosis (Houndmills, Basingstoke, England) 2012, 18:563-8.
51. Staples J, Ponsonby AL, Lim L: Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 2010, 340:c1640.
52. Fernandes de Abreu DA, Landel V, Feron F: Seasonal, gestational and postnatal influences on multiple sclerosis: the beneficial role of a vitamin D supplementation during early life. J Neurol Sci 2011, 311:64-8.
53. Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalban X et al: Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA neurology 2014, 71:306-14.
54. Hewison M: Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011, 7:337-45.
55. Gallo RL, Hooper LV: Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 2012, 12:503-16.
56. Bals R, Wilson JM: Cathelicidins-a family of multifunctional antimicrobial peptides. Cell Mol Life Sci 2003, 60:711-20.
57. Kahlenberg JM, Kaplan MJ: Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol 2013, 191:4895-901.
58. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA, Jr., Koeffler HP, Thadhani R: Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious diseasemortality in patients undergoing hemodialysis. Clin Infect Dis 2009, 48:418-24.
59. Bals R, Weiner DJ, Moscioni AD, Meegalla RL,Wilson JM: Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infection and immunity 1999, 67:6084-9.
60. Bhan I, Camargo CA, Jr., Wenger J, Ricciardi C, Ye J, Borregaard N, Thadhani R: Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol 2011, 127:1302-4 e1301.
61. Ralph AP, Lucas RM, Norval M: Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis 2013, 13:77-88.
62. Kamada N, Seo SU, Chen GY, Nunez G: Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013, 13:321-35.
63. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, Poulter L, Pachter L, Moffatt MF, Cookson WO: Disordered microbial communities in asthmatic airways. PLoS One 2010, 5: e8578.
64. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, Program NCS, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA: Topographical and temporal diversity of the human skin microbiome. Science 2009, 324:1190-2.
65. Gorman S, Weeden CE, Tan DH, Scott NM, Hart J, Foong RE, Mok D, Stephens N, Zosky G, Hart PH: Reversible control by vitamin D of granulocytes and bacteria in the lungs of mice: an ovalbumininducedmodel of allergic airway disease. PLoS One 2013, 8:e67823.
66. Lagishetty V, Misharin AV, Liu NQ, Lisse TS, Chun RF, Ouyang Y, McLachlan SM, Adams JS, Hewison M: Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology 2010, 151:2423-32.
67. Ooi JH, Li Y, Rogers CJ, Cantorna MT: Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfateinduced colitis. J Nutr 2013, 143:1679-86.
68. Scott CL, Aumeunier AM, Mowat AM: Intestinal CD103+ dendritic cells: master regulators of tolerance? Trends in immunology 2011, 32:412-9.
69. Mai V, McCrary QM, Sinha R, Glei M: Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and CaucasianAmerican volunteers. J Nutr 2009, 8:49.
70. Zeeuwen PL, Kleerebezem M, Timmerman HM, Schalkwijk J: Microbiome and skin diseases. Curr Opin Allergy Clin Immunol 2013, 13:514-20.
71. Tremezaygues L, Reichrath J: Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? Dermatoendocrinol 2011, 3:180-6.
72. Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, Mason RS, Finlay-Jones JJ, Hart PH: Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 2007, 179:6273-83.
73. Reinholz M, Ruzicka T, Schauber J: Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Annals of dermatology 2012, 24:126-35.
74. Bisgaard H, Vissing NH, Carson CG, Bischoff AL, Folsgaard NV, Kreiner-Moller E, Chawes BL, StokholmJ, Pedersen L, Bjarnadottir E, Thysen AH, Nilsson E,Mortensen LJ,Olsen SF, Schjørring S, Krogfelt KA, Lauritzen L, Brix S, Bønnelykke K: Deep phenotyping of the unselected COPSAC2010 birth cohort study. Clin Exp Allergy 2013, 43:1384-94.
75. Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C, De Simone C: Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. Am J Physiol Gastrointest Liver Physiol 2011, 301:G1004-13.
76. Rebel H, der Spek CD, Salvatori D, van Leeuwen JP, Robanus-Maandag EC, de Gruijl FR: UV exposure inhibits intestinal tumor growth and progression to malignancy in intestine-specific Apc mutant mice kept on low vitamin D diet. Int J Cancer 2014, 136:217-7.
77. Wada K, Tanaka H, Maeda K, Inoue T, Noda E, Amano R, Kubo N, Muguruma K, Yamada N, Yashiro M, Sawada T, Nakata B, Ohira M, Hirakawa K: Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 2009, 22:1021-5.
78. Korf H,Wenes M, Stijlemans B, Takiishi T, Robert S, Miani M, Eizirik DL, Gysemans C, Mathieu C: 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology 2012, 217:1292-300.
79. Waterhouse M, Tran B, Armstrong BK, BaxterC, Ebeling PR, EnglishDR, Gebski V, Hill C, Kimlin MG, Lucas RM, Venn A, Webb PM, Whiteman DC, Neale RE: Environmental, personal, and genetic determinants of response to vitamin D supplementation in older adults. J Clin Endocrinol Metab 2014, 99:E1332-40.
80. Liu PT,WheelwrightM, Teles R, Komisopoulou E, Edfeldt K, Ferguson B, Mehta MD, Vazirnia A, Rea TH, Sarno EN, Graeber TG, Modlin RL: MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med 2012, 18:267-73.
81. Adams JS, Hewison M: Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 2012, 523:95-102.
82. Zerwekh JE: Blood biomarkers of vitamin D status. Am J Clin Nutr 2008, 87:1087S-91S.
83. Ginde AA, Liu MC, Camargo CA, Jr.: Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009, 169:626-32.
84. Stokes CS, Volmer DA, Grunhage F, Lammert F: Vitamin D in chronic liver disease. Liver Int 2013, 33:338-52.
85. Blanton D, Han Z, Bierschenk L, Linga-Reddy MV, Wang H, Clare-Salzler M, Haller M, Schatz D, Myhr C, She JX, Wasserfall C, Atkinson M: Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes. Diabetes 2011, 60:2566-70.
86. Moller UK, Streym S, Heickendorff L, Mosekilde L, Rejnmark L: Effects of 25OHD concentrations on chances of pregnancy and pregnancy outcomes: a cohort study in healthy Danish women. Eur J Clin Nutr 2012, 66:862-8.
87. Armas LA, Hollis BW, Heaney RP: Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004, 89:5387-91.
88. Houghton LA, Vieth R: The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006, 84:694-7.
89. Lucas R, Group AI: Lower vitamin D status at first clinical diagnosis of central nervous system demyelination compared to matched controls. J Multiple Sclr 2009, 15:1393.
90. Mata-Granados JM, Vargas-Vasserot J, Ferreiro-Vera C, Luque de Castro MD, Pavon RG, Quesada Gomez JM: Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an online SPE-LC-MS/MS method. J Steroid Biochem Mol Biol 2010, 121:452-5.
91. Lappe JM, Heaney RP: Why randomized controlled trials of calcium and vitamin D sometimes fail. Dermatoendocrinol 2012, 4:95-100.
92. Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B: A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab 2012, 97:2644-52.
93. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC: Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303:1815-22.